| Code | CSB-RA025141MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to tezepelumab, targeting thymic stromal lymphopoietin (TSLP), a key epithelial cytokine involved in the initiation and persistence of allergic inflammatory responses. TSLP is released by epithelial cells in response to environmental triggers and activates multiple immune cell types, including dendritic cells, T cells, and mast cells, driving type 2 inflammation. Elevated TSLP expression has been implicated in various allergic and inflammatory conditions, including severe asthma, atopic dermatitis, chronic obstructive pulmonary disease, and eosinophilic esophagitis, making it a critical therapeutic target for understanding disease pathogenesis.
Tezepelumab, the reference antibody, is a human IgG2λ monoclonal antibody that binds TSLP and prevents its interaction with the heterodimeric TSLP receptor complex. This biosimilar provides researchers with a valuable tool for investigating TSLP-mediated inflammatory pathways, evaluating mechanisms of airway inflammation, studying epithelial-immune cell interactions, and exploring potential therapeutic interventions in type 2 inflammatory diseases.
There are currently no reviews for this product.